Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc....
Coronavirus
Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate
- Topline data expected as early as mid-2025 - SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart,...
Services PMI® at 53.5%; February 2025 Services ISM® Report On Business®
Business Activity Index at 54.4%; New Orders Index at 52.2%; Employment Index at 53.9%; Supplier Deliveries Index at 53.4% TEMPE, Ariz., March...
Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company...
Aligos Therapeutics Announces $105 Million Private Placement Financing
Proceeds expected to fund the start of the ALG-000184 Phase 2 clinical study Funding expected to extend cash runway into...
Services PMI® at 52.8%; January 2025 Services ISM® Report On Business®
Business Activity Index at 54.5%; New Orders Index at 51.3%; Employment Index at 52.3%; Supplier Deliveries Index at 53%; This...
XORTX to Present at Microcap Conference
CALGARY, Alberta, Jan. 29, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX...
ENA Respiratory Successfully Completes Phase Ib Dosing of Antiviral Host Defense Immune Enhancer INNA-051 Dry Powder Formulation in Older Adults and Advances Study in Young Adults
New intranasal formulation with significantly improved stability was well-tolerated and led to local activation of innate immune pathways in adults...
ISM Honors Manufacturing PMI® Outgoing Chair and Welcomes New Leader to Support Economic Reports
Timothy R. Fiore, Celebrated for His Exceptional Leadership, Retires from Role and Jeffrey P. Wincel Named as Incoming Chair TEMPE, Ariz.,...
Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT
FORT LAUDERDALE, FL / ACCESS Newswire / January 21, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company...
Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma
PDUFA action date of July 22, 2025, with priority reviewWOBURN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:...
XORTX Announces Change of Auditor
CALGARY, Alberta, Jan. 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX...
Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer
FORT LAUDERDALE, FL / ACCESSWIRE / January 15, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering...
Aptevo’s Peter Pavlik, PhD, Chairing Session on “Bi and Multispecific Biologics” at Cambridge Healthcare Institute’s Pep Talk 2025
Also giving an in-session talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," showcasing Aptevo's drug engineering...
NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025
SHELTON, CT / ACCESSWIRE / January 13, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing...
Generate:Biomedicines Provides Update on its Platform and Pipeline Powered by AI at the 43rd Annual J.P. Morgan Healthcare Conference
SOMERVILLE, Mass., Jan. 9, 2025 /PRNewswire/ -- Generate:Biomedicines ("Generate") today announced that Mike Nally, Chief Executive Officer, will provide an...
Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals
SHELTON, CT / ACCESSWIRE / January 8, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE American: NNVC) (the...
Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections
Data show favorable safety and tolerability with dosing up to 800 mg for 10 daysPlans to initiate human challenge study...
Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials
WOBURN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the...
Services PMI® at 54.1%; December 2024 Services ISM® Report On Business®
Business Activity Index at 58.2%; New Orders Index at 54.2%; Employment Index at 51.4%; Supplier Deliveries Index at 52.5% TEMPE,...